Skip to main content
SpringerLink
Log in

Serum Bcl-2 Values in Children with Pulmonary Hypertension

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

In this study, we aimed to assess levels of serum B cell lymphoma 2 (sBcl-2) in children, which has been implicated in the etiopathogenesis of pulmonary hypertension (PH), as well its association with tissue Doppler echocardiographic imaging (TDI) data and parameters used in the follow-up of PH. The sBcl-2 level was assessed in 35 children with PH (24 had eisenmenger syndrome, and 11 had idiopathic PH) and in 38 healthy children as controls. TDI was performed on 25 patients whose cardiac anatomy allowed the test. The respective sBcl-2 values in patients and controls were 35.69 ± 18.83 and 2.66 ± 7.95 ng/ml (p < 0.001). The sBcl-2 levels were significantly greater in the New York Heart Association (NYHA) functional class 3 patients than those in the NYHA class 2 patients (p = 0.033). The sBcl-2 value in patients who walked <475 m in the 6-min walk distance (6MWD) test was significantly greater than in those who walked ≥475 m (p = 0.038). The sBcl-2 level showed a negative correlation with ejection time measured at the septal anulus (p = 0.026) and a positive correlation with interventricular septum-Tei (p = 0.018). The results of this study showed for the first time that there is an increase in the levels of sBcl-2 as an inflammatory marker and that the sBcl-2 levels are associated with prognostic parameters in children with PH. Because sBcl-2 levels were greater in patients who walked <475 meters during the 6MWD test, we suggest 475 ms as the cut-off value for the 6MWD test to differentiate between a good and a bad prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chang SM, Lin CC, Hsiao SH, Lee CY, Yang SH, Lin SK et al (2007) Pulmonary hypertension and left heart function: insights from tissue Doppler imaging and myocardial performance index. Echocardiography 24(4):366–373

    Article  PubMed  Google Scholar 

  2. Colombel M, Symmans F, Gil S, O’Toole KM, Chopin D, Benson M et al (1993) Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 143(2):390–400

    PubMed Central  CAS  PubMed  Google Scholar 

  3. Cowan KN, Jones PL, Rabinovitch M (1999) Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res 84(10):1223–1233

    Article  CAS  PubMed  Google Scholar 

  4. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M (2000) Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 6(6):698–702

    Article  CAS  PubMed  Google Scholar 

  5. de Jong D, Prins FA, Mason DY, Reed JC, van Ommen GB, Kluin PM (1994) Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res 54(1):256–260

    PubMed  Google Scholar 

  6. Ecarnot-Laubriet A, Assem M, Poirson-Bichat F, Moisant M, Bernard C, Lecour S et al (2002) Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload. Biochim Biophys Acta 1586(3):233–242

    Article  CAS  PubMed  Google Scholar 

  7. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA et al (1995) Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71(5):1003–1007

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30(20):2493–2537

    Article  PubMed  Google Scholar 

  9. Gibbons GH, Dzau VJ (1994) The emerging concept of vascular remodeling. New Engl J Med 330(20):1431–1438

    Article  CAS  PubMed  Google Scholar 

  10. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR (2000) The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2(3):156–162

    Article  CAS  PubMed  Google Scholar 

  11. Gurbanov E, Shiliang X (2006) The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. Eur J Cardiothorac Surg 30(3):499–507

    Article  PubMed  Google Scholar 

  12. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F et al (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54(1 Suppl):S10–S19

    Article  CAS  PubMed  Google Scholar 

  13. Huang JB, Liu YL, Sun PW, Lv XD, Bo K, Fan XM (2010) Novel strategy for treatment of pulmonary arterial hypertension: enhancement of apoptosis. Lung 188(3):179–189

    Article  CAS  PubMed  Google Scholar 

  14. Levy M, Maurey C, Celermajer DS, Vouhe PR, Danel C, Bonnet D et al (2007) Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol 49(7):803–810

    Article  CAS  PubMed  Google Scholar 

  15. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C et al (2003) Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 89(1):55–64

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161(2 Pt 1):487–492

    Article  CAS  PubMed  Google Scholar 

  17. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M (2001) Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 17(4):647–652

    Article  CAS  PubMed  Google Scholar 

  18. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M et al (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86(7):499–504

    Article  CAS  PubMed  Google Scholar 

  19. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 24(62(25 Suppl)):D34–D41

    Article  Google Scholar 

  20. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P et al (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40(4):780–788

    Article  CAS  PubMed  Google Scholar 

  21. Stenmark KR, Fagan KA, Frid MG (2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99(7):675–691

    Article  CAS  PubMed  Google Scholar 

  22. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6(1):127–134

    CAS  PubMed  Google Scholar 

  23. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB (1998) Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 81(9):1157–1161

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Hacettepe University Scientific Research Projects Coordination Unit Ankara/Turkey. The project number is FON 12/02-29. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pediatric Cardiology, Hacettepe University Faculty of Medicine, Ihsan Doğramacı Childrens Hospital, 06100, Samanpazari, Ankara, Turkey

    Alper Akın, Dursun Alehan, Hayrettin Hakan Aykan, Süheyla Özkutlu, Sema Özer & Tevfik Karagöz

Authors
  1. Alper Akın
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dursun Alehan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hayrettin Hakan Aykan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Süheyla Özkutlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sema Özer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tevfik Karagöz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alper Akın.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akın, A., Alehan, D., Aykan, H.H. et al. Serum Bcl-2 Values in Children with Pulmonary Hypertension. Pediatr Cardiol 36, 579–583 (2015). https://doi.org/10.1007/s00246-014-1052-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-014-1052-x

Keywords

Search

Navigation